High-Grade Endometrial Carcinomas : Classification with Molecular Insights - 17/05/19
Doi : 10.1016/j.path.2019.02.003
Joseph W. Carlson, MD, PhD a, b, ⁎ 
, Denis Nastic, MD a, b
, Denis Nastic, MD a, b a Department of Oncology–Pathology, Karolinska Institutet, Stockholm SE-17176, Sweden
b Department of Clinical Pathology and Cytology, Karolinska University Hospital, Radiumhemmet P1:02, Stockholm SE-17176, Sweden
∗Corresponding author. Department of Clinical Pathology and Cytology, Karolinska University Hospital, Radiumhemmet P1:02, Stockholm SE-17176, Sweden.Department of Clinical Pathology and CytologyKarolinska University HospitalRadiumhemmet P1:02StockholmSE-17176Sweden
Abstract |
This article provides an overview of the current diagnosis of endometrial carcinoma subtypes and provides updates, including the most recent molecular findings from The Cancer Genome Atlas and others. Interpretation of relevant immunohistochemistry and critical diagnostic differential diagnosis with pitfalls are discussed.
Le texte complet de cet article est disponible en PDF.Keywords : Endometrial cancer, Molecular pathologic assessment, TCGA, POLE, MSI, p53, Prognosis
Plan
| Disclosure Statement: This work was funded by grants from the Radiumhemmets forskningsfonder and Region Stockholm. |
© 2019
Elsevier Inc. Tous droits réservés.
Vol 12 - N° 2
P. 343-362 - juin 2019 Retour au numéro
Article précédent
- Endometrial Carcinoma : Grossing, Frozen Section Evaluation, Staging, and Sentinel Lymph Node Evaluation
- Vinita Parkash, Oluwole Fadare
- Uterine Mesenchymal Tumors : Update on Classification, Staging, and Molecular Features
- Carlos Parra-Herran, Brooke E. Howitt
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?